title: Disseminated extracranial metastatic meningioma.
abstract: Meningiomas are usually low-grade, solitary lesions that rarely metastasize. In this group of central nervous system tumours, the higher grade subtypes are notorious for resistance to conventional chemo-radiation therapies. Recent studies have shown efficacy in the use of bevacizumab in patients with recurrent and, or progressive anaplastic meningioma. The authors report a case of a young patient with recurrent anaplastic meningioma who despite being treated with bevacizumab, progressed with disease dissemination to multiple extracranial sites. Although the majority of meningiomas are amendable to treatment, the higher grade subtypes remain therapeutically challenging. The unexpected resistance to anti-angiogenic therapy in this patient adds another layer of complexity to an elusive subset of a supposedly benign disease. This patient report reflects the need for in-depth studies, molecular characterization and overall, better disease understanding in order to improve prognosis for affected patients.
authors: Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
authors: Felicia H Z
authors: FH
authors: Chua
authors: Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. Electronic address: sharon_yy_low@nni.com.sg.
authors: Sharon Y Y
authors: SY
authors: Low
authors: Division of Medical Oncology, National Cancer Centre, Singapore.
authors: Chee K
authors: CK
authors: Tham
authors: Department of Pathology, Tan Tock Seng Hospital, Singapore.
authors: Cristine
authors: C
authors: Ding
authors: Department of Pathology, Tan Tock Seng Hospital, Singapore.
authors: Chin F
authors: CF
authors: Wong
authors: Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
authors: Colum P
authors: CP
authors: Nolan
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008579:Meningioma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D009362:Neoplasm Metastasis / Q000473:pathology; D011379:Prognosis
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Bevacizumab; Meningioma; Metastasis